GlassScriptPhysician profile
Viet H Pham
NPI 1053570184
$1,753.63
in general payments reported to CMS, 2019-2025
23 companies · $662 in 2025
The $662 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2021: $69.19 · 2022: $17.27 · 2023: $332 · 2024: $316 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $404.47 | 2023-2025 | |
| Integra Lifesciences Corporation | $173.62 | 2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Stryker Corporation | $125.14 | 2019-2025 | Xpress Loprofile, Clarifix Cryotherapy Device |
| Intersect Ent, INC. | $122.31 | 2019 | |
| Neurent Medical Limited | $119.41 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
| Arrinex, INC. | $117.24 | 2019 | |
| Aerin Medical INC. | $103.17 | 2025 | |
| Inspire Medical Systems, INC. | $77.01 | 2024 | Inspire |
| Kedrion Biopharma, INC. | $70.47 | 2023 | Rhogam Ultra-Filtered Plus, Kedrab, Albuked |
| Hikma Pharmaceuticals USA | $65.12 | 2023-2024 | Ryaltris |
| Optinose US, INC. | $64.99 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $51.99 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $48.41 | 2025 | Neffy |
| Smith+Nephew, INC. | $40.46 | 2023 | |
| Glaxosmithkline, LLC. | $28.09 | 2024-2025 | Nucala |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.33 | 2025 | Nuvent |
| Janssen Biotech, INC. | $21.45 | 2021 | |
| Btg International INC. | $17.48 | 2019 | |
| Phadia US INC. | $17.37 | 2023 | Immunocap |
| Alk-Abello, INC | $17.27 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.01 | 2021 | |
| Acclarent, INC | $12.80 | 2023 | Trudi Nav Cable |
| Merck Sharp & Dohme LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viet Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.